<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01665807</url>
  </required_header>
  <id_info>
    <org_study_id>SP1203</org_study_id>
    <nct_id>NCT01665807</nct_id>
  </id_info>
  <brief_title>A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine</brief_title>
  <official_title>A Time-Motion Study to Compare Self-vaccination With Intanza® Intradermal Influenza Vaccine to Nurse-administered Vaxigrip® Intramuscular Influenza Vaccine in Small Group Settings of Health Care Workers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brenda Coleman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mount Sinai Hospital, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that people working in an acute care hospital setting will be
      able to successfully self-administer the intradermal vaccine (Intanza) in less time than
      nurse-administration of the regular intramuscular influenza vaccine (Vaxigrip). The
      investigators also hypothesize that people administering the intradermal vaccine for the
      second time will take less time to successfully administer than people administering it for
      the first time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaccination of healthcare workers has been shown to reduce mortality and morbidity in the
      patients they care for, as well as reducing illness and absenteeism in the healthcare workers
      themselves, and healthcare worker vaccination programs have been shown to be cost-effective
      for hospitals because of the reduced absenteeism. Although influenza vaccination programs
      based on nurse-administered intramuscular vaccination are effective, easy access to
      vaccination for hospital staff remains a challenge, in part because of large numbers of staff
      working evening, night and weekend shifts. In addition, in the Canadian setting, increasing
      the efficiency of all hospital programs is a priority. If regular recipients of seasonal
      vaccine became accustomed to the practice, self-administration may significantly improve the
      efficiency of pandemic mass vaccination campaigns.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Administer Influenza Vaccine (in Seconds)</measure>
    <time_frame>Vaccination (Day 0)</time_frame>
    <description>Time required to explain vaccination, obtain consent, administer vaccine, and register vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability of Vaccine</measure>
    <time_frame>Follow up (Day 8)</time_frame>
    <description>The post-vaccination (Day 0) and follow-up (Day 8) questionnaires include questions on the participant's preference for intradermal or intramuscular injections and questions about their preference for administration by a healthcare provider or self-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success Rate</measure>
    <time_frame>Vaccination (Day 0)</time_frame>
    <description>Successful administration, defined as being able to self-vaccinate (or for RN to provide vaccine) on the first attempt. Will be calculated using the number of participants who are successful divided by the number of participants randomized to group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local &amp; Systemic Reactogenicity</measure>
    <time_frame>Follow up (Day 8)</time_frame>
    <description>Maximum self-reported diameter of redness, induration, and swelling, and maximum intensity and duration of itchiness, fever, muscle ache, joint pain, headache, fatigue, feeling unwell, and injection site pain as reported on Day 8 after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at Injection Site</measure>
    <time_frame>Follow up (Day 8</time_frame>
    <description>Self-perceived pain of injection will be recorded on an 11-point visual analogue scale immediately following vaccination (Day 0) and at follow-up (Day 8)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">868</enrollment>
  <condition>Influenza</condition>
  <condition>Vaccination Site Reactions (HT)</condition>
  <arm_group>
    <arm_group_label>Nurse-administered IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Self-administered intradermal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Self-administered intradermal influenza vaccine (Intanza 0.1 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat self-administration intradermal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intanza</intervention_name>
    <description>Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere</description>
    <arm_group_label>Self-administered intradermal</arm_group_label>
    <arm_group_label>Repeat self-administration intradermal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaxigrip</intervention_name>
    <description>Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere</description>
    <arm_group_label>Nurse-administered IM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically stable men or women 18 to 69 years of age (inclusive)

          -  Work in any capacity (including physicians and midwives with admitting privileges),
             volunteer, or student at participating hospital

          -  Able to read, understand, and respond to questionnaires

          -  Able to read, understand, and sign an informed consent form

          -  Available for follow-up for 8 days post-vaccination

          -  Participants in Part B (repeat administration) of the study must also have
             participated in the previous randomized control trial of self- versus
             nurse-administered intradermal influenza vaccine and must have attempted to
             self-administer the vaccine

        Exclusion Criteria:

          -  Already received 2012-13 influenza vaccine

          -  History of a severe reaction following influenza vaccination

          -  Known allergy to components of study vaccines (Intanza® or Vaxigrip®)

          -  History of Guillain-Barré Syndrome (GBS) within 8 weeks following influenza
             vaccination

          -  Acute febrile illness (&gt;37.9ºC orally) within the past 48 hours (participation may be
             deferred until recovery for these subjects)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda L Coleman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melissa Barton</last_name>
    <role>Study Director</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Moore</last_name>
    <role>Study Director</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shelly A McNeil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Canadian Centre for Vaccinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanne M Langley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Canadian Centre for Vaccinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott A Halperin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Canadian Centre for Vaccinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allison J McGeer, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Vaccinology</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2012</study_first_submitted>
  <study_first_submitted_qc>August 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2012</study_first_posted>
  <results_first_submitted>July 31, 2013</results_first_submitted>
  <results_first_submitted_qc>July 31, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 1, 2013</results_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mount Sinai Hospital, Canada</investigator_affiliation>
    <investigator_full_name>Brenda Coleman</investigator_full_name>
    <investigator_title>Clinical Scientist</investigator_title>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>vaccine</keyword>
  <keyword>administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sites: 2 acute care hospitals in Canada Dates: September 25, 2012 to November 20, 2012</recruitment_details>
      <pre_assignment_details>People who had self-administered intradermal influenza vaccine in past were only eligible for the &quot;repeat&quot; self-administration arm.
No other pre-assignment eligibility criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nurse-administered IM</title>
          <description>Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
Vaxigrip : Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere</description>
        </group>
        <group group_id="P2">
          <title>Repeat Self-administration Intradermal</title>
          <description>Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
Intanza : Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere</description>
        </group>
        <group group_id="P3">
          <title>Self-administered Intradermal</title>
          <description>Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
Intanza : Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="411"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="402"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="409"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nurse-administered IM</title>
          <description>Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
Vaxigrip : Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere</description>
        </group>
        <group group_id="B2">
          <title>Repeat Self-administered Intradermal</title>
          <description>Self-administration (2) of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
Intanza : Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere</description>
        </group>
        <group group_id="B3">
          <title>Self-administered Intradermal</title>
          <description>Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
Intanza : Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="411"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="402"/>
            <count group_id="B4" value="871"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="386"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="391"/>
                    <measurement group_id="B4" value="835"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.0" spread="13.2"/>
                    <measurement group_id="B2" value="40.2" spread="11.3"/>
                    <measurement group_id="B3" value="41.2" spread="12.6"/>
                    <measurement group_id="B4" value="42.5" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="295"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="282"/>
                    <measurement group_id="B4" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="411"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="402"/>
                    <measurement group_id="B4" value="871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Administer Influenza Vaccine (in Seconds)</title>
        <description>Time required to explain vaccination, obtain consent, administer vaccine, and register vaccination</description>
        <time_frame>Vaccination (Day 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nurse-administered IM</title>
            <description>Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
Vaxigrip : Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere</description>
          </group>
          <group group_id="O2">
            <title>Repeat Self-administration Intradermal</title>
            <description>Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
Intanza : Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere</description>
          </group>
          <group group_id="O3">
            <title>Self-administered Intradermal</title>
            <description>Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
Intanza : Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Administer Influenza Vaccine (in Seconds)</title>
          <description>Time required to explain vaccination, obtain consent, administer vaccine, and register vaccination</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="18.0" upper_limit="235.3"/>
                    <measurement group_id="O2" value="182.0" lower_limit="42.5" upper_limit="671.1"/>
                    <measurement group_id="O3" value="62.6" lower_limit="29.8" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acceptability of Vaccine</title>
        <description>The post-vaccination (Day 0) and follow-up (Day 8) questionnaires include questions on the participant's preference for intradermal or intramuscular injections and questions about their preference for administration by a healthcare provider or self-vaccination.</description>
        <time_frame>Follow up (Day 8)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate</title>
        <description>Successful administration, defined as being able to self-vaccinate (or for RN to provide vaccine) on the first attempt. Will be calculated using the number of participants who are successful divided by the number of participants randomized to group.</description>
        <time_frame>Vaccination (Day 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nurse-administered IM</title>
            <description>Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
Vaxigrip : Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere</description>
          </group>
          <group group_id="O2">
            <title>Repeat Self-administration Intradermal</title>
            <description>Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
Intanza : Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere</description>
          </group>
          <group group_id="O3">
            <title>Self-administered Intradermal</title>
            <description>Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
Intanza : Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate</title>
          <description>Successful administration, defined as being able to self-vaccinate (or for RN to provide vaccine) on the first attempt. Will be calculated using the number of participants who are successful divided by the number of participants randomized to group.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="401"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local &amp; Systemic Reactogenicity</title>
        <description>Maximum self-reported diameter of redness, induration, and swelling, and maximum intensity and duration of itchiness, fever, muscle ache, joint pain, headache, fatigue, feeling unwell, and injection site pain as reported on Day 8 after vaccination</description>
        <time_frame>Follow up (Day 8)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain at Injection Site</title>
        <description>Self-perceived pain of injection will be recorded on an 11-point visual analogue scale immediately following vaccination (Day 0) and at follow-up (Day 8)</description>
        <time_frame>Follow up (Day 8</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nurse-administered IM</title>
          <description>Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
Vaxigrip : Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere</description>
        </group>
        <group group_id="E2">
          <title>Repeat Self-administration Intradermal</title>
          <description>Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
Intanza : Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere</description>
        </group>
        <group group_id="E3">
          <title>Self-administered Intradermal</title>
          <description>Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
Intanza : Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brenda L. Coleman, PhD,</name_or_title>
      <organization>Mount Sinai Hospital, IDERU</organization>
      <phone>416-586-4800 ext 4538</phone>
      <email>bcoleman@mtsinai.on.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

